Revenue - Schedule of Deferred Revenue (Details) - License and collaboration revenue - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended |
|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2026 |
|
| Contract with Customer, Asset (Liability) [Roll Forward] | ||
| Beginning balance | $ (56.3) | |
| Additions related to development cost reimbursement received | (20.0) | |
| Additions due to milestone achieved related to FDA approval | (100.0) | |
| Revenue recognized | 187.7 | |
| Ending balance | $ 11.4 | 11.4 |
| Exact Science License Agreement | ||
| Contract with Customer, Asset (Liability) [Roll Forward] | ||
| Revenue recognized | $ 182.5 | 187.7 |
| Contract asset | $ 11.4 |